Scopus BioPharma Past Earnings Performance
Past criteria checks 0/6
Scopus BioPharma has been growing earnings at an average annual rate of 45.3%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
45.3%
Earnings growth rate
61.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Scopus BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -9 | 4 | 5 |
| 31 Mar 23 | 0 | -9 | 6 | 4 |
| 31 Dec 22 | 0 | -12 | 9 | 3 |
| 30 Sep 22 | 0 | -16 | 14 | 2 |
| 30 Jun 22 | 0 | -16 | 16 | 1 |
| 31 Mar 22 | 0 | -28 | 15 | 14 |
| 31 Dec 21 | 0 | -27 | 13 | 15 |
| 30 Sep 21 | 0 | -21 | 7 | 15 |
| 30 Jun 21 | 0 | -21 | 5 | 15 |
| 31 Mar 21 | 0 | -14 | 4 | 9 |
| 31 Dec 20 | 0 | -11 | 3 | 7 |
| 30 Sep 20 | 0 | -11 | 3 | 8 |
| 30 Jun 20 | 0 | -10 | 3 | 8 |
| 31 Mar 20 | 0 | -3 | 2 | 0 |
| 31 Dec 19 | 0 | -3 | 2 | 0 |
| 30 Sep 19 | 0 | -2 | 2 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 0 | 0 |
Quality Earnings: SCPS is currently unprofitable.
Growing Profit Margin: SCPS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SCPS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SCPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCPS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SCPS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.